Significant Options Activity on Monday: WWD, AOSL, AVTR
Alpha & Omega Semiconductor Options Activity: AOSL experienced options trading volume of 1,856 contracts, equating to about 185,600 underlying shares, with significant activity in the $22.50 strike call option expiring December 19, 2025.
Avantor Inc Options Activity: AVTR saw a high options trading volume of 53,637 contracts, representing approximately 5.4 million underlying shares, particularly in the $9 strike put option expiring December 19, 2025.
Comparison of Trading Volumes: The options trading volumes for both AOSL and AVTR accounted for 44% and 43.6% of their respective average daily trading volumes over the past month.
Resource for Further Information: For more details on available expirations for AOSL, AVTR, or WWD options, StockOptionsChannel.com is recommended as a resource.
Trade with 70% Backtested Accuracy
Analyst Views on AVTR
About AVTR
About the author

- Software Selloff: After three consecutive days of gains, the iShares Tech-Expanded Software Sector ETF (NYSE:IGV) fell over 3% on Wednesday, indicating a decline in market confidence towards the software sector, which could impact investor sentiment towards tech stocks overall.
- Strong Jobs Data but Severe Revisions: Although January's nonfarm payrolls rose by 130,000, significantly exceeding economists' expectations of 70,000, the total U.S. job growth for 2025 was drastically revised down to just 181,000, highlighting the fragility of economic recovery and potentially raising concerns about future growth.
- Unexpected Drop in Unemployment Rate: The unemployment rate fell from 4.4% to 4.3%, which appears positive on the surface; however, this contrasts sharply with the downward revisions in job growth, possibly leading investors to question the economic outlook.
- Robinhood's Poor Market Performance: Robinhood Markets Inc. (NASDAQ:HOOD) saw its stock tumble 12% following a revenue miss and disappointing cryptocurrency trading results, reflecting market concerns about its future profitability and potentially undermining investor confidence.
- Weak Earnings Guidance: Avantor's forecast for 2026 earnings falls short of market expectations, leading to a decline in share price, which reflects investor concerns about the company's future performance and may undermine confidence.
- Revenue Decline Expected: The company anticipates a decrease in future revenues, with analysts suggesting that this trend could negatively impact the overall financial health of Avantor, potentially leading to further stock price pressure.
- CEO Turnaround Plan: Avantor's CEO has outlined a turnaround strategy to address margin pressures, aiming to improve financial conditions through operational optimization and cost control, thereby restoring market trust.
- Analyst Perspectives: Analysts generally believe that the current stock discount is justified, reflecting a cautious market outlook on the company's future profitability, which may influence investor buying decisions.
- Sales Performance Decline: Avantor reported sales of $1.66 billion, slightly above the consensus of $1.64 billion, yet reflecting a year-over-year decline of 1.4%, indicating pressure in a competitive market that impacts investor confidence.
- Organic Sales Drop: Despite a positive foreign currency impact of 3.1%, the negative 0.4% from M&A led to a 4.1% decline in organic sales, highlighting challenges in core operations that could affect future growth potential.
- Profitability Outlook: Avantor expects adjusted earnings per share for fiscal 2026 to range between $0.77 and $0.83, below the consensus of $0.90, indicating pressure on profitability that may raise investor concerns about future performance.
- Market Performance Assessment: Analyst William Blair notes Avantor's shares trade at 11.4 times the midpoint of the 2026 adjusted EBITDA guide, lower than peers at 17.6 times, reflecting cautious market sentiment regarding its growth and margin profile, potentially affecting stock recovery.

- Strategic Reorganization: Avantor announced a restructuring into two new business units after three months of implementing its revival plan, aiming to enhance market responsiveness through a customer-centric structure, thereby strengthening its competitive edge.
- Financial Performance: Q4 2025 revenue was $1.66 billion, down 4% year-over-year, with an adjusted gross margin of 31.5%, indicating profitability challenges amid market pressures, while management projects organic revenue decline of 2.5% to 0.5% for 2026.
- Investment Commitment: The company plans to invest $10 million to $15 million in 2026 to upgrade the VWR e-commerce platform, emphasizing the importance of digital transformation for customer engagement, aiming to enhance customer experience and market share.
- Market Outlook: Management's outlook for 2026 is cautious, with expected EBITDA margin contraction of 100 to 150 basis points due to investment and cost pressures, highlighting the challenges of maintaining profitability in an uncertain market environment.
- Acadia Healthcare Stock Surge: Acadia Healthcare's stock rose 10% after investor David Einhorn announced his purchases, reflecting market optimism about the new management's ability to enhance performance, which could improve future profitability.
- Vertiv's Upbeat Guidance: Vertiv's stock jumped nearly 20% due to its optimistic guidance for 2026, with orders accelerating significantly in Q4, surpassing Wall Street expectations and indicating strong demand in the data center market.
- Unity Software's Downgrade: Unity Software's shares fell nearly 30% after issuing a first-quarter revenue outlook between $480 million and $490 million, below analysts' expectations of $492.1 million, raising concerns about its future growth prospects.
- Smurfit WestRock Order Improvement: Smurfit WestRock's stock soared over 10% after revealing improved product orders in late December, with expectations of reaching $7 billion in profits by 2030, highlighting its long-term growth potential.
- 2026 Earnings Guidance Cut: Avantor projects adjusted earnings per share between $0.77 and $0.83 for 2026, falling short of the consensus estimate of $0.91, indicating potential weaknesses in future profitability that may undermine investor confidence.
- Q4 Performance Exceeds Expectations: Despite Q4 revenue reaching $1.7 billion, slightly exceeding consensus by $20 million, the figure remained flat year-over-year, suggesting challenges in revenue growth that could impact future market performance.
- Segment Underperformance: The Laboratory Solutions and Bioscience Production segments generated $1.1 billion and $548 million in net sales, respectively, with year-over-year declines of approximately 1% and 2%, reflecting weakened market demand that may necessitate strategic adjustments.
- Adjusted EBITDA Decline: The company's adjusted EBITDA dropped approximately 18% year-over-year to $252.2 million, missing analysts' expectations of $261.6 million, indicating pressures on cost control and profitability that could influence future investment decisions.







